Opposing TNF-/IL-1β- and BMP-2-activated MAPK signaling pathways converge on Runx2 to regulate BMP-2-induced osteoblastic differentiation

Cell Death and Disease

Volumn 5, Issue 4, 2014, Pages

  Huang, R L ^a   Yuan, Y ^a   Tu, J ^a   Zou, G M ^b   Li, Q ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

BMP 2; IL 1 ; MAPK; Osteoblastic differentiation; Runx2; TNF

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE;

3T3 CELL LINE; ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CELL LINE; CYTOLOGY; DRUG EFFECTS; HUMAN; METABOLISM;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTERLEUKIN-1BETA; MAP KINASE SIGNALING SYSTEM; MICE; MODELS, BIOLOGICAL; OSTEOBLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SMAD PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901006699     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.101     Document Type: Article

References (59)

1. Rosen V. BMP2 signaling in bone development and repair. Cytokine Growth Factor Rev 2009; 20: 475-480.
2. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery 2008; 62: ONS423-ONS431; discussion ONS431.
3. McKay WF, Peckham SM, Badura JM. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int Orthop 2007; 31: 729-734.
4. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011; 11: 471-491.
5. Tumialan LM, Rodts GE. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion. Spine J 2007; 7: 509-510.
6. Smucker JD, Rhee JM, Singh K, Yoon ST, Heller JG. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) 2006; 31: 2813-2819.
7. Taher F, Lebl DR, Hughes AP, Girardi FP. Contralateral psoas seroma after transpsoas lumbar interbody fusion with bone morphogenetic protein-2 implantation. Spine J 2013; 13: e1-e5.
8. Robin BN, Chaput CD, Zeitouni S, Rahm MD, Zerris VA, Sampson HW. Cytokine-mediated inflammatory reaction following posterior cervical decompression and fusion associated with recombinant human bone morphogenetic protein-2: a case study. Spine (Phila Pa 1976) 2010; 35: E1350-E1354.
9. McClellan JW, Mulconrey DS, Forbes RJ, Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006; 19: 483-486.
10. Xu R, Bydon M, Sciubba DM, Witham TF, Wolinsky JP, Gokaslan ZL et al. Safety and efficacy of rhBMP2 in posterior cervical spinal fusion for subaxial degenerative spine disease: analysis of outcomes in 204 patients. Surg Neurol Int 2011; 2: 109.
11. Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med 2013; 158: 890-902.
12. Beidas OE, Deschamps-Braly JC, Morgan AM, Workman MC, Knotts CD, Denny AD et al. Safety and efficacy of recombinant human bone morphogenetic protein 2 on cranial defect closure in the pediatric population. J Craniofac Surg 2013; 24: 917-922.
13. Cahill KS, Chi JH, Day A, Claus EB. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009; 302: 58-66.
14. Hoffmann MF, Jones CB, Sietsema DL. Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in posterolateral lumbar spine fusion: complications in the elderly. J Orthop Surg Res 2013; 8: 1.
15. Pape HC, Marcucio R, Humphrey C, Colnot C, Knobe M, Harvey EJ. Trauma-induced inflammation and fracture healing. J Orthop Trauma 2010; 24: 522-525.
16. Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Invest 2011; 41: 1361-1366.
17. Ritting AW, Weber EW, Lee MC. Exaggerated inflammatory response and bony resorption from BMP-2 use in a pediatric forearm nonunion. J Hand Surg [Am] 2012; 37: 316-321.
18. MacDonald KM, Swanstrom MM, McCarthy JJ, Nemeth BA, Guliani TA, Noonan KJ. Exaggerated inflammatory response after use of recombinant bone morphogenetic protein in recurrent unicameral bone cysts. J Pediatr Orthop 2010; 30: 199-205.
19. Lee KB, Murray SS, Taghavi CE, Song KJ, Brochmann EJ, Johnson JS et al. Bone morphogenetic protein-binding peptide reduces the inflammatory response to recombinant human bone morphogenetic protein-2 and recombinant human bone morphogenetic protein-7 in a rodent model of soft-tissue inflammation. Spine J 2011; 11: 568-576.
20. Ratanavaraporn J, Furuya H, Tabata Y. Local suppression of pro-inflammatory cytokines and the effects in BMP-2-induced bone regeneration. Biomaterials 2012; 33: 304-316.
21. Tan Y, Montgomery SR, Aghdasi BG, Inoue H, Kaner T, Tian H et al. The effect of corticosteroid administration on soft-tissue inflammation associated with rhBMP-2 use in a rodent model of inflammation. Spine (Phila Pa 1976) 2013; 38: 806-813.
22. Xiong C, Daubs MD, Montgomery SR, Aghdasi B, Inoue H, Tian H et al. BMP-2 adverse reactions treated with human dose equivalent dexamethasone in a rodent model of soft-tissue inflammation. Spine (Phila Pa 1976) 2013; 38: 1640-1647.
23. Huang RL, Yuan Y, Zou GM, Liu G, Tu J, Li Q. LPS-stimulated inflammatory environment inhibits BMP-2-induced osteoblastic differentiation through crosstalk between TLR4/ MyD88/NF-kappaB and BMP/Smad signaling. Stem Cells Dev 2014; 23: 277-289.
24. ten DP. Bone morphogenetic protein signal transduction in bone. Curr Med Res Opin 2006; 22(Suppl 1): S7-11.
25. Chen G, Deng C, Li YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012; 8: 272-288.
26. Huang YF, Lin JJ, Lin CH, Su Y, Hung SC. c-Jun N-terminal kinase 1 negatively regulates osteoblastic differentiation induced by BMP2 via phosphorylation of Runx2 at Ser104. J Bone Miner Res 2012; 27: 1093-1105.
27. Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 2009; 19: 71-88.
28. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
29. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
30. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012; 92: 689-737.
31. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75: 50-83.
32. Bokui N, Otani T, Igarashi K, Kaku J, Oda M, Nagaoka T et al. Involvement of MAPK signaling molecules and Runx2 in the NELL1-induced osteoblastic differentiation. FEBS Lett 2008; 582: 365-371.
33. Liu H, Liu Y, Viggeswarapu M, Zheng Z, Titus L, Boden SD. Activation of c-Jun NH(2)- terminal kinase 1 increases cellular responsiveness to BMP-2 and decreases binding of inhibitory Smad6 to the type 1 BMP receptor. J Bone Miner Res 2011; 26: 1122-1132.
34. Yang N, Wang G, Hu C, Shi Y, Liao L, Shi S et al. Tumor necrosis factor alpha suppresses the mesenchymal stem cell osteogenesis promoter miR-21 in estrogen deficiency-induced osteoporosis. J Bone Miner Res 2013; 28: 559-573.
35. Zhao B, Grimes SN, Li S, Hu X, Ivashkiv LB. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med 2012; 209: 319-334.
36. Lacey DC, Simmons PJ, Graves SE, Hamilton JA. Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. Osteoarthritis Cartilage 2009; 17: 735-742.
37. Lee KB, Taghavi CE, Song KJ, Sintuu C, Yoo JH, Keorochana G et al. Inflammatory characteristics of rhBMP-2 in vitro and in an in vivo rodent model. Spine (Phila Pa 1976) 2011; 36: E149-E154.
38. Lee KB, Taghavi CE, Murray SS, Song KJ, Keorochana G, Wang JC. BMP induced inflammation: a comparison of rhBMP-7 and rhBMP-2. J Orthop Res 2012; 30: 1985-1994.
39. Bae HW, Strenge KB, Ashraf N, Badura JM, Peckham SM, McKay WF. Transient soft-tissue edema associated with implantation of increasing doses of rhBMP-2 on an absorbable collagen sponge in an ectopic rat model. J Bone Joint Surg Am 2012; 94: 1845-1852.
40. Hsu W, Polavarapu M, Riaz R, Larson A, Jared JD, Ghodasra J et al. Characterizing the host response to rhBMP-2 in a rat spinal arthrodesis model. Spine (Phila Pa 1976) 2013; 38: E691-E698.
41. Ao A, Hao J, Hopkins CR, Hong CC. DMH1 a novel BMP small molecule inhibitor, increases cardiomyocyte progenitors and promotes cardiac differentiation in mouse embryonic stem cells. PLoS One 2012; 7: e41627.
42. Neely MD, Litt MJ, Tidball AM, Li GG, Aboud AA, Hopkins CR et al. DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. ACS Chem Neurosci 2012; 3: 482-491.
43. Lin FH, Chang JB, McGuire MH, Yee JA, Brigman BE. Biphasic effects of interleukin-1beta on osteoblast differentiation in vitro. J Orthop Res 2010; 28: 958-964.
44. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141: 3956-3964.
45. Hess K, Ushmorov A, Fiedler J, Brenner RE, Wirth T. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone 2009; 45: 367-376.
46. Glass GE, Chan JK, Freidin A, Feldmann M, Horwood NJ, Nanchahal J. TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of musclederived stromal cells. Proc Natl Acad Sci USA 2011; 108: 1585-1590.
47. Yamashita M, Otsuka F, Mukai T, Otani H, Inagaki K, Miyoshi T et al. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2- induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogenactivated protein kinase pathway. J Endocrinol 2008; 196: 601-613.
48. Matsumoto Y, Otsuka F, Takano M, Mukai T, Yamanaka R, Takeda M et al. Estrogen and glucocorticoid regulate osteoblast differentiation through the interaction of bone morphogenetic protein-2 and tumor necrosis factor-alpha in C2C12 cells. Mol Cell Endocrinol 2010; 325: 118-127.
49. Tang Y, Xie H, Chen J, Geng L, Chen H, Li X et al. Activated NF-kB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling. Stem Cells Dev 2013; 22: 668-678.
50. Mukai T, Otsuka F, Otani H, Yamashita M, Takasugi K, Inagaki K et al. TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem Biophys Res Commun 2007; 356: 1004-1010.
51. Yamazaki M, Fukushima H, Shin M, Katagiri T, Doi T, Takahashi T et al. Tumor necrosis factor alpha represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-kappaB. J Biol Chem 2009; 284: 35987-35995.
52. Eda H, Shimada H, Beidler DR, Monahan JB. Proinflammatory cytokines, IL-1beta and TNF-alpha, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NFkappaB pathway but not p38 pathway in osteoblasts. Rheumatol Int 2011; 31: 1525-1530.
53. Ferreira E, Porter RM, Wehling N, O'Sullivan RP, Liu F, Boskey A et al. Inflammatory cytokines induce a unique mineralizing phenotype in mesenchymal stem cells derived from human bone marrow. J Biol Chem 2013; 288: 29494-29505.
54. Greenblatt MB, Shim JH, Glimcher LH. Mitogen-activated protein kinase pathways in osteoblasts. Annu Rev Cell Dev Biol 2013; 29: 63-79.
55. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009; 24: 1434-1449.
56. Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G, Caverzasio J. Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003; 18: 2060-2068.
57. Higuchi C, Myoui A, Hashimoto N, Kuriyama K, Yoshioka K, Yoshikawa H et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 2002; 17: 1785-1794.
58. Vinals F, Lopez-Rovira T, Rosa JL, Ventura F. Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett 2002; 510: 99-104.
59. Jun JH, Yoon WJ, Seo SB, Woo KM, Kim GS, Ryoo HM et al. BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity. J Biol Chem 2010; 285: 36410-36419.